Cargando…
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects
Background and Objective: HEC30654 is a selective 5-HT6 receptor antagonist that was safe and well-tolerated in preclinical models of Alzheimer’s disease. The objective of this double-blind, randomized, placebo-controlled clinical trial was to evaluate the safety, tolerability, and pharmacokinetic p...
Autores principales: | Li, Xiaojiao, Gao, Lei, Liu, Jingrui, Zhang, Hong, Chen, Hong, Yang, Lizi, Wu, Min, Li, Cuiyun, Zhu, Xiaoxue, Ding, Yanhua, Sun, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416768/ https://www.ncbi.nlm.nih.gov/pubmed/34489712 http://dx.doi.org/10.3389/fphar.2021.726536 |
Ejemplares similares
-
A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(®)) in Chinese healthy subjects
por: Zhang, Hong, et al.
Publicado: (2021) -
Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
por: Liu, Jingrui, et al.
Publicado: (2021) -
Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018) -
A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
por: Zhang, Hong, et al.
Publicado: (2021) -
First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects
por: Zhang, Hong, et al.
Publicado: (2022)